News

AZCERT recently made its MedSafety Scan decision support system available to health care professionals during the COVID-19 pandemic. In case you missed the announcement, and to keep you informed on how MedSafety Scan is progressing, we are sharing with you a copy of our first newsletter sent to all MSS registrants.

With no drug yet proven to reduce deaths due to COVID-19, scores of clinical trials are underway testing already available drugs (marketed and investigational) in the hope that one or a combination of these will be effective. Unfortunately, outside of these trials, many patients are being treated with drugs that have potentially lethal side effects which raises the very important question…. Are these drugs saving more lives than they might be taking?

The Cardiac Safety Research Consortium has posted a comprehensive list of resources related to cardiac safety, drug development and COVID-19

We hope the following COVID-19 update will have value as you face challenges related to the safe use of medicines for COVID-19. It is being sent to all healthcare providers and/or research scientists registered to receive information from the CredibleMeds website. Today, there are many drugs known to cause torsades de pointes (TdP) that are either being tested in clinical trials or used off-label, sometimes with little or no medical supervision.

USA Today article warns of QT risk with some drugs being tested

Dangerous Drug Combinations for a Dangerous Virus

Recent updates to the QTDrugs to Avoid Lists made in December 2019 and March 2020 are detailed in this blog post.

From a trusted source: Dr. Ray Woosley discusses the facts about the Coronavirus.

Chlorprothixene, an antipsychotic drug, marketed in several European countries, has been added to the list of drugs with Known Risk of Torsades. The category assigned to the antidepressant, clomipramine, has been changed.

Two drugs have been added to the Known Risk of Torsades list.